Original article Continuing trends in pathological stage migration in radical prostatectomy specimens

Prostate-specific antigen (PSA) screening has resulted in a profound clinical stage migration. Extracapsular extension (ECE) presents a poor prognosis after radical prostatectomy (RP). In this study the trends in rate of ECE for cancers detected by PSA screening between 1987, when PSA screening became routine in the United States, and 2001, were examined. The clinical outcome of patients (total 1505; 888 clinical Tlc, 614 clinical T2, and 3 clinical T3) with prostate cancer diagnosed by PSA screening and treated with RP without neoadjuvant hormonal therapy was analyzed. The primary outcome variable was ECE rate with respect to year of treatment for a given tumor stage, preoperative PSA level, biopsy Gleason score, and surgical Gleason score. Logistic regression analysis was used to identify predictors of ECE. Biochemical relapse-free survival (bRFS) by year of treatment was analyzed by Kaplan-Meier Curve. Rate of ECE decreased from 65.8 to 25.2% during the 15-year study duration. Multivariate analysis of clinical tumor stage, age, preoperative serum PSA level, and Gleason score confirmed that year of treatment was an independent predictor of ECE. Six-year bRFS rates (by years of treatment) were 75.1% for 1987 to 1994 and 82.6% for 1995 to 2001 (P-value 0.0022). PSA screening has resulted in a downward pathological stage migration. These observations demonstrate improved biochemical failure

[1]  R. Peschel,et al.  Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. , 2003, The Lancet. Oncology.

[2]  Laurence R. Paquette,et al.  Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.

[3]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[4]  M. Kattan,et al.  Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Levin,et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Stamey,et al.  Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. , 1998, The Journal of urology.

[7]  H. Levin,et al.  Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. , 1998, Urology.

[8]  M. Kattan,et al.  Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? , 1997, The Journal of urology.

[9]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[10]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[11]  C. Smart,et al.  The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence‐‐Data from the Utah Cancer Registry , 1996, Cancer.

[12]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[13]  H. Adami,et al.  The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. , 1995, The Journal of urology.

[14]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[15]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[16]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[17]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[18]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[19]  R. Kane,et al.  Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .

[20]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[21]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[22]  E. Klein,et al.  Early continence after radical prostatectomy. , 1992, The Journal of urology.

[23]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[24]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[25]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[26]  R L Vessella,et al.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.

[27]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[28]  I. Thompson,et al.  Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.

[29]  G. Murphy,et al.  The national survey of prostate cancer in the United States by the American College of Surgeons. , 1982, The Journal of urology.

[30]  Laurence R. Paquette,et al.  Predictors of extracapsular extension and positive margins in African American and white men. , 2003, Urologic oncology.

[31]  R. Kane,et al.  The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.